• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by QuidelOrtho Corporation

    6/16/26 4:31:57 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $QDEL alert in real time by email
    8-K
    QuidelOrtho Corp false 0001906324 0001906324 2026-06-16 2026-06-16
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): June 16, 2026

     

     

    QUIDELORTHO CORPORATION

    (Exact name of Registrant as specified in its Charter)

     

     

     

    Delaware   001-41409   87-4496285

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    9975 Summers Ridge Road, San Diego, California 92121

    (Address of principal executive offices, including zip code)

    (858) 552-1100

    (Registrant’s telephone number, including area code)

    N/A

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, $0.001 Par Value   QDEL   The Nasdaq Stock Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    On June 16, 2026, QuidelOrtho Corporation (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The following are the final voting results on proposals considered and voted upon at the Annual Meeting, all of which are described in the proxy statement for the Annual Meeting, as filed with the U.S. Securities and Exchange Commission on April 27, 2026.

    Proposal No. 1

    The Company’s stockholders elected the ten director nominees to the Company’s Board of Directors by the votes set forth in the table below:

     

    Name   Votes For   Votes Withheld   Broker Non-Votes

    Brian J. Blaser

      56,664,418   560,787   7,088,721

    Kenneth F. Buechler, Ph.D.

      56,008,344   1,216,861   7,088,721

    John R. Chiminski

      56,788,541   436,664   7,088,721

    Evelyn S. Dilsaver

      56,676,148   549,057   7,088,721

    R. Scott Huennekens

      56,634,433   590,772   7,088,721

    Edward L. Michael

      56,585,483   639,722   7,088,721

    Mary Lake Polan, M.D., Ph.D., M.P.H.

      56,148,684   1,076,521   7,088,721

    Ann D. Rhoads

      56,741,863   483,342   7,088,721

    Kenneth J. Widder, M.D.

      56,078,638   1,146,567   7,088,721

    Joseph D. Wilkins Jr.

      56,587,197   638,008   7,088,721

    Proposal No. 2

    The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers by the votes set forth in the table below:

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes
    55,716,067   1,486,910   22,228   7,088,721

    Proposal No. 3

    The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the Company’s 2026 fiscal year by the votes set forth in the table below:

     

    Votes For   Votes Against   Abstentions
    64,197,113   97,367   19,446


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: June 16, 2026

     

    QUIDELORTHO CORPORATION
    By:  

    /s/ Nathaniel B. Sisitsky

    Name:   Nathaniel B. Sisitsky
    Its:   Chief Legal Officer and Corporate Secretary
    Get the next $QDEL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QDEL

    DatePrice TargetRatingAnalyst
    5/7/2026$12.50Buy → Hold
    Jefferies
    10/7/2025$33.00Buy → Neutral
    Citigroup
    5/8/2025$44.00Hold → Buy
    Jefferies
    12/11/2024$44.00 → $50.00Neutral → Buy
    Citigroup
    12/10/2024$43.00Hold
    Jefferies
    9/19/2024$42.00 → $50.00Neutral
    UBS
    9/5/2024$40.00 → $57.00Hold → Buy
    Craig Hallum
    3/4/2024$70.00 → $42.00Neutral → Sell
    UBS
    More analyst ratings

    $QDEL
    SEC Filings

    View All

    QuidelOrtho Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - QuidelOrtho Corp (0001906324) (Filer)

    6/23/26 4:04:14 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 8-K filed by QuidelOrtho Corporation

    8-K - QuidelOrtho Corp (0001906324) (Filer)

    6/16/26 4:31:57 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SD filed by QuidelOrtho Corporation

    SD - QuidelOrtho Corp (0001906324) (Filer)

    5/11/26 4:05:44 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    QuidelOrtho downgraded by Jefferies with a new price target

    Jefferies downgraded QuidelOrtho from Buy to Hold and set a new price target of $12.50

    5/7/26 8:02:07 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho downgraded by Citigroup with a new price target

    Citigroup downgraded QuidelOrtho from Buy to Neutral and set a new price target of $33.00

    10/7/25 8:58:45 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho upgraded by Jefferies with a new price target

    Jefferies upgraded QuidelOrtho from Hold to Buy and set a new price target of $44.00

    5/8/25 9:44:58 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Busky Joseph M. bought $79,742 worth of shares (3,370 units at $23.66) (SEC Form 4)

    4/A - QuidelOrtho Corp (0001906324) (Issuer)

    2/19/26 4:18:05 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Strobeck Matthew bought $239,586 worth of shares (10,000 units at $23.96), increasing direct ownership by 56% to 27,775 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    2/13/26 4:20:08 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Financial Officer Busky Joseph M. bought $79,742 worth of shares (3,370 units at $23.66) (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    2/13/26 12:44:31 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    QuidelOrtho Appoints Micah Young as Chief Financial Officer

    Seasoned medical technology finance executive brings more than two decades of leadership at global public companiesSAN DIEGO, June 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho" or the "Company"), a leading global provider of diagnostic solutions, today announced the appointment of Micah Young as Chief Financial Officer, effective July 6, 2026. Mr. Young will succeed Joseph M. Busky, who previously announced his retirement as Chief Financial Officer and will serve in an advisory role to support a smooth transition. "Micah is an accomplished public-company CFO with deep medical technology expertise

    6/23/26 7:12:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho and Allo Hope Foundation Join Forces to Advance Education, Connection and Early Testing for Alloimmunized Pregnancies

    SAN DIEGO, June 2, 2026 /PRNewswire/ -- QuidelOrtho, a global leader in diagnostic innovation, and the Allo Hope Foundation, a nonprofit dedicated to supporting families and clinicians managing maternal alloimmunization, announced a new collaboration focused on improving prenatal care through education, early testing and stronger connections between laboratory providers, clinicians and patients. Maternal red blood cell alloimmunization is a serious, often misunderstood condition that can pose significant risks to the child during pregnancy. Red cell antibodies can cross the placenta and destroy fetal and neonatal red blood cell

    6/2/26 7:12:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    When Blood Compatibility Becomes a Pregnancy Risk

    SAN DIEGO, May 21, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL), a global leader of in vitro diagnostics, has released episode 58 of its Science Bytes podcast, focusing on hemolytic disease of the fetus and newborn (HDFN) – a serious but often underrecognized condition driven by maternal alloimmunization. Hosted by Michelle Mullens, Global Product Manager of Portfolio Solutions for Transfusion Medicine at QuidelOrtho, the episode features Bethany Weathersby, Founder and Executive Director of the Allo Hope Foundation. Together, they explore how red blood cell antibo

    5/21/26 9:18:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Widder Kenneth J was granted 1,183 shares, increasing direct ownership by 3% to 45,073 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    6/9/26 4:07:11 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Polan Mary Lake Ph D was granted 973 shares, increasing direct ownership by 5% to 20,442 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    6/9/26 4:06:39 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Buechler Kenneth F was granted 2,156 shares, increasing direct ownership by 2% to 110,906 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    6/9/26 4:06:09 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Financials

    Live finance-specific insights

    View All

    QuidelOrtho Reports First Quarter 2026 Financial Results

    ― LEX Diagnostics Acquisition Expected to Accelerate Growth in Point-of-Care Molecular Diagnostics ―― Key Product Launches in U.S. and International Markets Expected to Drive Future Growth ―― Company Updates Full-Year 2026 Financial Guidance ― SAN DIEGO, May 5, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the first quarter ended March 29, 2026. Key First Quarter 2026 Results:(all comparisons are to the prior year period)Total revenue was $620

    5/5/26 4:05:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TTP Group Announces the Sale of LEX Diagnostics

    TTP today announced the acquisition by QuidelOrtho Corporation (NASDAQ:QDEL), a global leader in in vitro diagnostics, of LEX Diagnostics Limited, a UK-based molecular diagnostics company and a spin-out of TTP Group. Founded in 2020, LEX Diagnostics originated from a TTP innovation programme to translate a breakthrough in ultra-fast thermal control into a commercially viable diagnostic solution. This work led to the development of a point-of-care molecular testing platform capable of delivering PCR results in minutes. "At TTP, we identified the opportunity for ultra-fast thermal cycling to unlock the real potential of PCR at the point-of-care," said Dr Andrew Baker-Campbell, Chair and f

    4/20/26 7:56:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 Guidance

    SAN DIEGO, April 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, today announced preliminary unaudited revenue for the first quarter of 2026, ended March 29, 2026, and provided an update on its full-year 2026 financial guidance. The Company also announced its plan to release its full first quarter 2026 financial results on Tuesday, May 5, 2026, after the market closes. Preliminary Unaudited First Quarter 2026 RevenueThe Company currently expects preliminary unaudited revenue, as reported, o

    4/15/26 4:15:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

    SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    12/6/24 10:11:24 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13D/A filed by QuidelOrtho Corporation

    SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)

    11/21/24 5:10:19 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

    SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    11/14/24 1:28:35 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QDEL
    Leadership Updates

    Live Leadership Updates

    View All

    QuidelOrtho Appoints Micah Young as Chief Financial Officer

    Seasoned medical technology finance executive brings more than two decades of leadership at global public companiesSAN DIEGO, June 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho" or the "Company"), a leading global provider of diagnostic solutions, today announced the appointment of Micah Young as Chief Financial Officer, effective July 6, 2026. Mr. Young will succeed Joseph M. Busky, who previously announced his retirement as Chief Financial Officer and will serve in an advisory role to support a smooth transition. "Micah is an accomplished public-company CFO with deep medical technology expertise

    6/23/26 7:12:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics

    – Marks a Milestone in QuidelOrtho's Plans to Accelerate Growth in Point-of-Care Molecular Diagnostics –– Expands Portfolio with Ultra-Fast PCR Platform Designed to Deliver Results in Approximately Ten Minutes or Less –– Company Expects to Initiate U.S. Commercial Launch of the LEX VELO System Later This Year –SAN DIEGO, April 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today it has completed the acquisition of LEX Diagnostics ("LEX") for cash consideration of approximately $100 million. The LEX VELO System received U.S. Food and Drug Administration ("FDA") 510(k) clearance and

    4/20/26 7:12:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer

    SAN DIEGO, March 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, is pleased to announce the appointment of Nathaniel "Nate" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. He will report to Brian Blaser, President and Chief Executive Officer, and will lead QuidelOrtho's global legal, compliance and corporate governance functions. Mr. Sisitsky brings more than 25 years of legal and governance experience advising public companies across life sciences and technology sectors.

    3/24/26 7:00:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care